Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MethylGene and Pharmion have reported that the European Medicines Agency or EMEA and the European Commission, designated MGCD0103, a histone deacetylase inhibitor, as an orphan medicinal product for the treatment of acute myelogenous leukemia in the EU.
Subscribe to our email newsletter
MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor and is currently in one Phase I combination clinical trial with Taxotere for solid tumors, two Phase I/II combination trials with Vidaza for hematological malignancies and with Gemzar for pancreatic cancer, and five Phase II clinical trials in hematological malignancies.